RE:PDACCRO - Contract Research Organization
The CRO for GOBLET is AIO - Asklepios Tumorzentrum Hamburg
Yet we have not been advised as to the CRO for the Adaptive Phase 3 Trial.
From my lay position it seems to me AIO is the obvious choice for the Adaptive Phase 3 Trial.
Alas shareholders are completely in the dark as to the CRO for the Phase 3 trial.
ONC certainly knows the CRO; yet here us shareholders wait for material information that would be very useful in making an investment decision.
It should also be noted that ONC had outside help in designing GOBLET and that help is not longer on the scene.